Novelion Therapeutics Observes Rare Disease Day
February 28 2018 - 7:00AM
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and
Others Worldwide in Supporting Awareness of Rare Diseases
VANCOUVER, British Columbia, Feb.
28, 2018 (GLOBE NEWSWIRE) -- Novelion
Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases, today announced its alliance
with the National Organization for Rare Disorders (NORD), Rare
Diseases Europe (EURORDIS), Canadian Organization of Rare Disorders
(CORD), and The Global Genes Project in observance of the annual
Rare Disease Day.
Chief Operating Officer Jeff
Hackman commented, "Novelion is proud to join our community to
raise awareness of rare diseases. Mindful of the challenges these
patients, their families and caregivers face, we are motivated by a
passion to support advocacy and aspire to develop innovative
treatments for patients with rare diseases."
In the United States, a rare
disease is defined as one that affects fewer than 200,000 persons.
According to the National Institutes of Health (NIH), there are
nearly 7,000 rare diseases affecting nearly 30 million Americans.
Rare Disease Day was established by EURORDIS and was first observed
in Europe in 2008. In 2009, EURORDIS partnered with NORD for this
initiative in the U.S. For more information about Rare Disease Day,
visit www.rarediseaseday.org.
About
Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to
developing new standards of care for individuals living with rare
diseases. Novelion has a diversified commercial portfolio through
its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which
includes MYALEPT® and JUXTAPID®, and is also developing zuretinol
acetate for the potential treatment of inherited retinal disease
caused by underlying mutations in RPE65 or LRAT genes. The company
seeks to advance its portfolio of rare disease therapies by
investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations &
Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novelion Therapeutics Inc. via Globenewswire
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Sep 2023 to Sep 2024